Molecular biology plays an important role in the diagnosis and treatment of cancer. On a biological level, the development of cancer is characterized by the acquisition of genetic mutations which cause abnormal cell growth, eventually resulting in malignant disease. Understanding how molecular damage can cause these cancer-driving mutations can help design optimal treatment regimens
-
The eukaryotic translation initiation factor eIF4E is an oncogene elevated in an estimated 30% of cancers. The traditional view is that eIF4E drives proliferation and survival by increasing t...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
High-throughput short-read DNA sequencing has revolutionized our ability to measure genetic variation in the form of single-nucleotide polymorphisms (SNPs) in human genomes. However, ~75% of...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
One of the hallmarks of human cancers is genetic instability. My colleagues and I recently identified a remarkable association between human papillomavirus (HPV) and genomic structural variat...
There is growing pressure to implement new generation sequencing platform in hospital emergency rooms. The utility would be obvious: identifying unknown pathogens form cerebrospinal fluid/pl...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Pharmcogenomics (PGx) is the 2nd potential clinical application of genomic medicine, preceded by genomic application for cancer. In the recently published, 2012 Institute of Medicine report o...
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...